ArticleCancer management and research2026
A Failure Pattern Analyses in NSCLC Patients Received Immuno-Radiotherapy and a Dosimetric Feasibility Study of a Three-Ladder Radiotherapy Strategy.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to analyze failure patterns in stage III non-small cell lung cancer (NSCLC) patients treated with immuno-radiotherapy and to dosimetrically evaluate a novel three-ladder radiotherapy (3L-RT) strategy designed to address the observed local control deficit. Methods: Clinical outcomes and failure patterns were retrospectively analyzed in 89 consecutive stage III NSCLC patients (2020-2023) treated with simultaneous integrated boost intensity modulated radiotherapy (SIB-IMRT) combined with immunotherapy. Separately, a dosimetric planning study was conducted to compare the feasibility of the proposed 3L-RT strategy (prescribing 74 Gy to GTV, 60 Gy to PTV-g, and 54 Gy to PTV-c) against conventional radiotherapy (PTV-c 60 Gy) on a distinct patient cohort, with and without 4D-CT simulation. Results: Median follow-up was 23.2 months. Median progression-free survival (PFS) and overall survival (OS) were 19.4 and 41.1 months, respectively. Immuno-neoadj independently predicted superior PFS (HR: 0.32, p < 0.001) and OS (HR: 0.25, p = 0.013). Among 43 progression events (48.3%), local failure (53.5%) predominated, driven by primary tumor progression. Distant metastases occurred in 51.2% (pulmonary, osseous, and intracranial sites most frequent). In the dosimetric comparison, the 3L-RT strategy reduced cardiopulmonary exposure versus conventional plans: lung V20 decreased from 20.2% to 19.6%, cardiac V30 from 9.55% to 8.7%, and effective dose to immune cells (EDIC) from 3.9 Gy to 3.7 Gy (p < 0.001). Dose reductions persisted with 4D-CT integration. Conclusion: Within the studied clinical cohort, immunotherapy combined with SIB-IMRT correlates with favorable survival, yet local failure remains a predominant challenge. The proposed 3L-RT strategy is dosimetrically feasible, enabling targeted GTV dose escalation while sparing critical organs. These dosimetric findings support the rationale for future prospective clinical trials to evaluate whether this strategy can improve local control and survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.